Valneva SE (VALN) Tuesday said it has started a Phase 1 study to evaluate the safety and immunogenicity of VLA1601, the company's second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV).
Valneva plans to enroll about 150 participants in the study who are aged between 18 and 49 years in the United States.
Topline data from the trial are expected in the first half of 2025.
There are currently no vaccines or effective treatments available for ZIKV.
For comments and feedback contact: editorial@rttnews.com
Business News